Page last updated: 2024-12-07

n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119545
CHEMBL ID26085
SCHEMBL ID16174561
MeSH IDM0145953

Synonyms (11)

Synonym
cystemustine
cmso2en2
n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea
n-(2-chloroethyl)-n'-(2-(methylsulfonyl)ethyl)-n-nitrosourea
urea, n-(2-chloroethyl)-n'-(2-(methylsulfonyl)ethyl)-n-nitroso-
CHEMBL26085
79955-36-5
unii-07g51a6fma
07g51a6fma ,
DTXSID60229972
SCHEMBL16174561

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic and pharmacodynamic properties of cystemustine were investigated."( Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients.
Armand, JP; Cellarier, E; Cholle, P; Curé, H; Labarre, P; Madelmont, JC; Marchenay, C; Maurizis, JC; Ouabdesselam, R; Terret, C, 2002
)
0.31
" Pharmacokinetics analysis showed mono- or biphasic cystemustine blood disposition with a mean a half-life of 4 min and mean terminal half-life of 49 min."( Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients.
Armand, JP; Cellarier, E; Cholle, P; Curé, H; Labarre, P; Madelmont, JC; Marchenay, C; Maurizis, JC; Ouabdesselam, R; Terret, C, 2002
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" Previously, we have shown that O6-benzyl-N2-acetylguanosine (BNAG), an MGMT inhibitor, can be combined with cystemustine by intravenous administration, and increases the antitumour effect of cystemustine in resistant human melanoma."( Melanoma-cell toxicity of cystemustine combined with O6-benzyl-N2-acetylguanosine.
Buchdahl, C; Debiton, E; Glasser, AL; Laval, F; Madelmont, JC; Mounetou, E; Rolhion, C, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
"A trial of cystemustine, a cysteamine nitrosourea, was carried out on 34 patients with advanced malignancies at increasing dosage of the drug over a period of up to 190 days in seven or eight cycles."( Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
Godenèche, D; Madelmont, JC; Mathé, G; Meyniel, G; Misset, JL; Triana, BK, 1992
)
0.28
" The influence of circadian dosing time upon its toxicities was first investigated in a total of 368 synchronized male B6D2F1 mice."( Circadian rhythm in toxic effects of cystemustine in mice: relevance for chronomodulated delivery.
Chollet, P; Filipski, E; Kwiatkowski, F; Lemaigre, G; Levi, F; Martineau-Pivoteau, N; Rolhion, C, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID121693Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose 60 umol/kg (infinity-50-100%survivals)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121673Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose 120 umol/kg1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121694Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose 80 umol/kg1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID101247Number of survivors/ number of animals tested at the dose of 20 mg/Kg, iv; 0/61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID101249Number of survivors/ number of animals tested at the dose of 40 mg/Kg, iv; 6/61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID101251Number of survivors/ number of animals tested at the dose of 60 mg/Kg, iv; 6/61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID101245Number of survivors/ number of animals tested at the dose of 120 mg/Kg, iv; 0/61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121687Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose 20 umol/kg1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID101369Number of survivors/ number of animals tested at the dose of 80 mg/Kg, iv; 1/61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121690Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose 40 umol/kg (infinity-50-100%survivals)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.33)18.7374
1990's13 (36.11)18.2507
2000's20 (55.56)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.99 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (35.90%)5.53%
Reviews1 (2.56%)6.00%
Case Studies1 (2.56%)4.05%
Observational0 (0.00%)0.25%
Other23 (58.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]